Zevra Therapeutics (ZVRA) Enterprise Value (2016 - 2025)
Zevra Therapeutics (ZVRA) has disclosed Enterprise Value for 10 consecutive years, with -$128.6 million as the latest value for Q4 2025.
- For the quarter ending Q4 2025, Enterprise Value fell 85.05% year-over-year to -$128.6 million, compared with a TTM value of -$199.5 million through Sep 2025, down 123.22%, and an annual FY2025 reading of -$128.6 million, down 85.05% over the prior year.
- Enterprise Value was -$128.6 million for Q4 2025 at Zevra Therapeutics, up from -$199.5 million in the prior quarter.
- Across five years, Enterprise Value topped out at -$43.3 million in Q3 2023 and bottomed at -$202.6 million in Q2 2025.
- Average Enterprise Value over 5 years is -$95.4 million, with a median of -$76.8 million recorded in 2022.
- The sharpest move saw Enterprise Value plummeted 3122.28% in 2021, then surged 46.72% in 2022.
- Year by year, Enterprise Value stood at -$112.3 million in 2021, then increased by 26.69% to -$82.4 million in 2022, then increased by 17.76% to -$67.7 million in 2023, then dropped by 2.6% to -$69.5 million in 2024, then plummeted by 85.05% to -$128.6 million in 2025.
- Business Quant data shows Enterprise Value for ZVRA at -$128.6 million in Q4 2025, -$199.5 million in Q3 2025, and -$202.6 million in Q2 2025.